# Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis

> **NCT00443950** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 150 (estimated)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00443950
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2007-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00443950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00443950, "Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00443950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*